XML 50 R34.htm IDEA: XBRL DOCUMENT
v3.25.4

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment Reporting [Abstract] |
Schedule of Reconciled Consolidated Net Loss | Segment revenue and significant segment expenses which are regularly reported to the CODM are included within the table below and are reconciled to consolidated net loss:
| Year ended December 31,
| 2025 |  | 2024 |  | 2023
Revenue: |  |  |  |  |
Product revenue, net | $ | 5,420 |  |  | $ | — |  |  | $ | — |
Collaboration and license revenue | 2,276 |  |  | 1,039 |  |  | 4,013 |
Total revenue, net | 7,696 |  |  | 1,039 |  |  | 4,013 |
Less: |  |  |  |  |
Cost of product revenue | (1,076) |  |  | — |  |  | — |
Research and development expenses |  |  |  |  |
Paltusotine | (68,337) |  |  | (51,229) |  |  | (46,772) |
Atumelnant | (48,131) |  |  | (24,524) |  |  | (13,118) |
Other research and development programs | (33,322) |  |  | (26,010) |  |  | (20,421) |
Research and development personnel expenses | (102,677) |  |  | (70,772) |  |  | (53,446) |
Research and development stock-based compensation | (50,344) |  |  | (40,667) |  |  | (22,633) |
Other research and development (1) | (29,247) |  |  | (26,954) |  |  | (12,137) |
Total research and development expenses | (332,058) |  |  | (240,156) |  |  | (168,527) |
Selling, general and administrative |  |  |  |  |
External selling, general and administrative expenses | (90,013) |  |  | (38,733) |  |  | (20,362) |
Selling, general and administrative personnel expenses | (60,638) |  |  | (32,285) |  |  | (19,428) |
Selling, general and administrative stock-based compensation | (40,680) |  |  | (28,719) |  |  | (18,304) |
Total selling, general and administrative expenses | (191,331) |  |  | (99,737) |  |  | (58,094) |
Total other income, net | 51,632 |  |  | 40,916 |  |  | 13,277 |
Income tax expense | (180) |  |  | — |  |  | — |
Loss on equity method investment | — |  |  | (470) |  |  | (5,198) |
Segment and consolidated net loss | $ | (465,317) |  |  | $ | (298,408) |  |  | $ | (214,529) |
(1)Other research and development is comprised of non-personnel related research and development indirect costs incurred for the benefit of multiple research and development programs, including depreciation, and other facility-based expenses, such as rent expense.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration